信达生物：Initial validation of overseas expansion capabilities

3 Jan 2025 CMB International Global Markets | Equity Research | Company Update Innovent Biologics (1801 HK) Initial validation of overseas expansion capabilities Out-licensed global rights of DLL3 ADC to Roche. Innovent has out-licensed the global rights of IBI3009, a novel DLL3 ADC, to Roche through a blockbuster deal. The drug candidate obtained IND approval for a global Ph1 study in Dec 2024. Innovent and Roche will jointly focus on the early-stage development of the asset before Roche assumes full respo ...